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Abstract 
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common malignancy. The Barcelona Clinical 
Liver Cancer System (BCLC), guides the treatment of patients with HCC. Platelet to lymphocyte ratio (PLR) is an 
inflammatory marker used as a prognostic factor disease of HCC. An increase in PLR indicates higher host's 
inflammatory response and is associated with aggressive HCC behaviour, according to BCLC.  
AIM: This study aims to determine the PLRs between among the degrees of BCLC (The Barcelona Clinic Liver 
Cancer) in HCC patients at Haji Adam Malik General Hospital in Medan during 2015-2016. 
METHODS: This retrospective study involved 166 patients with HCC who were then classified by the BCLC 
guidelines. PLRs among the patient's degrees of BCLC were compared using Kruskal Wallis test.  
RESULTS: A total of 166 HCC patients, 129 (77.7%) were men and 37 (22.3%) were women. The PLR value has 
a median value of 17841with the lowest value of 1776 and the highest value of 223684. There were differences in 
PLR levels with various BCLC stages in patients with HCC at Haji Adam Malik Hospital during 2015-2016 (p = 
0.026).  
CONCLUSION: There were differences in PLR levels with various BCLC stages in patients with HCC at Haji 
Adam Malik Hospital during 2015-2016. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Hepatocellular carcinoma (HCC) is the fifth 
most common malignancy, with more than 30 cases 
per 100,000 people each year in Southeast and 
Central Asia. In the United States, the incidence has 
doubled over the past 20 years. The highest incidence 
of HCC was found in South East Asian Indonesia with 
a level of age standard (ASR) of 31.9 per 100,000 in 
men and 10.2 per 100,000 in women. HCC relates to 
some risk factors, including chronic hepatitis virus 
infection, Non-Alcoholic Fatty Liver Disease, 
alcoholism, and aflatoxin-contaminated food. The 
most common one is chronic Hepatitis B virus 
infection. Majority patients with chronic HBV infection 
have no typical symptoms, although the viruses are 
active and transmit into another person. 
Guidelines for clinical practice is critical in 
directing and standardising the management of the 
disease. The Barcelona Clinical Liver Cancer System 
(BCLC), grades HCC and guides its. This staging 
system is complete and accurate since it does not 
only evaluate tumour characteristics, performance 
status and liver function but also connects disease 
staging to its treatment course [1].  Platelet and 
lymphocyte counts are basic haematological 
examinations that are very easy, fast to apply 
everyday and cheap. Platelet to lymphocyte ratio 
(PLR) is an inflammatory marker used as a prognostic 
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factor in various types of diseases. An increase in 
PLR indicates that the host's inflammatory response 
increased. This is associated with more aggressive 
tumour characteristics [2]. 
This study aims to determine the PLRs 
between among the degrees of BCLC (The Barcelona 
Clinic Liver Cancer) in HCC patients at Haji Adam 
Malik General Hospital in Medan during 2015-2016. 
 
 
Material and Methods 
 
Data collection 
A retrospective study conducted at Internal 
Medicine Clinic Haji Adam Malik General Hospital in 
Medan from January 1, 2015, to December 31, 2016, 
in patients diagnosed with HCC. A total of 166 
patients that had lymphocyte and platelet counts, liver 
function test, AFP, liver USG and 3-phase Liver CT 
Scans were recruited in this study and then grouped 
into BCLC A, B, C and D [2]. 
 
Statistics 
All data were analysed using SPSS version 
22. Demographic data were presented in numbers 
and percentages. Comparison of platelet to 
lymphocyte ratio between the degrees of BCLC of 
HCC patients was analysed using the Kruskal Wallis 
test. 
 
 
Results  
 
The demographic data of 166 HCC patients, 
consisted of 129 male patients (77.7%) and 37 female 
patients (22.3%). The median age of HCC patients 
was 52.8 years (20-83). Hepatitis B virus infection was 
found in 84.9% of patients, while hepatitis C virus 
infection and other causes were in 4.8% and 10.2% 
patients, respectively.  
Table 1: Demographic characteristics of subjects 
Variable n = 166 
Gender 
Male 
Female 
 
129 (77.7 %)
a 
37 (22.3%) 
Age 52.8 (20-83)
c
 
Aetiology 
Hepatitis B 
Hepatitis C 
Other 
 
141 (84.9 %)
a
 
8 (4.8 %) 
17 (10.2 %) 
LIM 15.1 (1.9 – 60.8)
c
 
PLR 17841 (1776 – 223684)
c 
PLT 280819 ± 138268
b 
BCLC 
A 
B 
C 
D 
 
12 (7.2 %)
a
 
54 (32.5 %) 
76 (45.8 %) 
24 (14.5 %) 
Lymphocytes have a median value of 15.10 
U/L with the lowest value of 1.90 U/L and the highest 
value of 60.80 U/L, and the PLR had a median value 
of 17841.57 with the lowest value of 1776.32 and the 
highest value of 223684.21. The average platelet 
value was 280819.28 ± 138268.57 then for the BCLC 
staging system; the most was BCLC class C (45.8%), 
followed by BCLC B (32.5%), BCLC D (14.5%) and 
BCLC A (7.2%) (Table 1). 
Table 2: Comparison of PLR levels of HCC patients on BCLC 
staging 
BCLC PLR P 
A 
B 
C 
D 
18534 (2509 -61267) 
14069 (1776 - 223684) 
18469 (2536 – 119117) 
30007(3724 – 117500) 
0,026 
 
There were differences in PLR levels with 
various BCLC stages in patients with HCC. 
 
Figure 1: Comparison PLRs ratios between degrees of BCLC A, B, 
C and D 
 
 
Discussion 
 
In this study, it was found that the number of 
male HCC patient (77.7%) and female (22.3%) (Table 
1). This is relevant with the research conducted by 
GLOBOCAN, cancer research (2012) which states 
that HCC patients are dominated with a male than a 
female with a ratio between 2: 1 to 4: 1. [3], the 
incidence of HCC in men was 40.0 and in women 15.3 
per 100,000 population. Yuen et al., (2000) [4], and 
Cheung et al., (2006) [5], published that the 
percentage of male HCC patients compared to female 
4: 1. 
The median age of HCC patients in this study 
was 52.8 years (Table 1). Yuen et al., (2000) [4] and 
Cheung et al., (2006) [5] obtained that the median age 
of HCC patients in Hong Kong 61 and 63 years old. 
Park (2005) [6], studying HCC, with the highest 
incidence of  HCC at the age of 55 years old. An 
analysis of subgroups in the United States examines 
Hispanic and African-American ethnicities, the highest 
incidence of HCC at the age of 45-65 years.  
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The most common aetiology of the incidence 
of HCC, according to this study, is hepatitis B infection 
(Table 1). This is also relevant to other studies. 
Chronic HBV infection has been known to be closely 
related to the incidence of HCC. HBV infection 
contributes greatly to the incidence of HCC and its 
mortality rate, around 63.9% of the incidence of HCC 
is caused by HBV infection [7], [8]. 
HBV carcinogenicity to the liver occurs 
through a chronic inflammatory process, increased 
hepatocyte proliferation, integration of HBV DNA into 
host cell DNA and HBV specific protein activity 
interacting with liver cells. Changes in hepatocytes 
from inactive conditions to replicate active cells 
determine the level of liver carcinogenesis. The 
coincidence of HBV infection with exposure to other 
oncogenic agents such as aflatoxin can cause HCC 
without going through liver cirrhosis condition. The 
amount of HBV and its genotypic factors affect the 
pathogenesis of HCC.  
Other causes of HCC development are 
because HBV DNA can integrate with human genes, 
which can interfere with endogenous tumour 
suppressor and various other gene regulators or can 
also facilitate the emergence of proto-oncogenic 
activity. This imbalance between pro-oncogenic 
factors and tumour suppressor signals support the 
growth of HCC [10]. 
The effect of fat metabolic disorders, 
inflammation also contributes to insulin resistance. 
Proinflammatory cytokines and transcription factors 
are overexpressed in fatty tissue and liver. Obesity, 
which is mild chronic inflammation, is a risk factor for 
insulin resistance and NAFLD. There are induced by 
excessive intake, which is an early cause of 
decreasing insulin sensitivity. Obesity makes fat 
accumulation and activates the signalling flow of c-
JunN-terminal kinase (JNK) and NF-κB) which results 
in increased production of proinflammatory cytokines 
such as TNF-α and IL-6. In addition to various 
proteins in fatty tissue such as adiponectin and leptin, 
it is considered the main link between obesity, insulin 
resistance and related inflammatory diseases. This 
series of inflammation is a risk factor for the 
development of HCC [11]. 
Inflammation is a protective immune response 
to dangerous stimuli such as pathogens and dead 
cells, which are regulated by the host. Inflammation is 
the stimulation of tumour progression. Tissue 
biomarkers reflect SIRS conditions that show 
prognostic value. Some haematological parameters 
include modified Glasgow Prognostic Score (mGPS), 
C-reactive protein (CRP), neutrophil to lymphocyte 
ratio (NLR), inflammation-based index (IBI) and 
platelet to lymphocyte ratio (PLR) [12]. 
Virchow suggested the relationship between 
inflammation and cancer through the theory of 
leukocyte infiltration in tumours, which generally 
characterise cancer cells. Since then, more evidence 
and research have suggested that the inflammatory 
response correlates with tumour progressions such as 
angiogenesis and tumour invasion. Invasion and 
migration of tumour cells are related to inflammatory 
cells, including lymphocytes, neutrophils and platelets. 
Platelets are important effector cells in hemostasis, 
recently have a role in the inflammatory response. 
Platelets recognise and kill pathogens and release 
various immune mediators and endothelial cell 
responses [13]. 
PLR is the result of calculating the ratio of 
platelet counts to lymphocytes. As an important 
component of the host's defence system, lymphocytes 
play an important role in various types of neoplasms. 
Tumour-infiltrating lymphocytes affect the outcome of 
patients with malignancy. High platelet counts indicate 
a poor prognosis, where lymphocyte infiltration around 
the tumour is associated with a better prognosis [14]. 
In this study, there were significant 
differences in PLRs to various BCLC stages in HCC 
patients (Table 2) and (Figure 1). Therefore PLR can 
be used to determine the progressiveness of HCC. 
The use of BCLC as a staging tool has been used 
universally. BCLC staging includes radiological 
assessment, while PLR is simpler, using routine blood 
tests [15]. Zheng et al. (2017) [16] stated that 
increasing NLR and PLR indicates a poor prognostic 
in HCC patients. NLR and PLR were reliable and 
cheap biomarkers in clinical decisions to the treatment 
of HCC. 
Lee et al. (2015) [17], published that HCC 
patients with higher platelet counts had a greater risk 
of extrahepatic metastasis. With a large platelet count, 
it can secrete large amounts of VEGF (vascular 
endothelial growth factor) and PDGF (platelet-derived 
growth factor). This is an important factor for 
angiogenesis, cell proliferation and tumour metastatic. 
Ma W. et al. (2016) [15] found that increasing PLR 
indicated a poor prognostic in HCC patients. Wang H. 
et al., (2017) [18] stated that high PLR values are 
associated with the presence of HBV infection, tumour 
size, age over 60 years, and higher levels of BCLC. 
PLR indicates a poor prognostic in HCC patients. 
Likewise, in a similar study by Lin WF et al., (2018) 
[19], the same results were found where high PLR 
had worse prognostics. 
In conclusion, there is a significant difference 
in PLR in BCLC degrees.  
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